Oxford-headquartered molecular diagnostics innovator, Sense Biodetection has entered into a strategic distribution agreement with Cruinn Diagnostics Ltd. for the Irish market. Cruinn, a leading supplier in the healthcare and laboratory market, is among the network of planned EU distribution partners authorized to market Veros COVID-19. Sense received CE Mark for Veros COVID-19 earlier this month.
Sense says that Veros COVID-19 is the first and only fully integrated, easy-to-use molecular diagnostic test that provides laboratory-quality results in 15 minutes. Unconstrained by an instrument or reader and using a patient-friendly anterior nasal swab, Veros COVID-19 was designed for use in hospital emergency departments, pharmacies, care homes, and urgent care, providing accurate results.
Analytical performance testing has demonstrated that Veros COVID-19 is over 1,000 times more sensitive than widely used antigen tests. It brings the performance of lab-based PCR tests, which detect approximately 30 per cent more true positives than antigen tests, directly to the point of care.
Ryan Roberts, Chief Commercial Officer of Sense, said: “Cruinn’s reputation for customer service and innovative point-of-care products is best in class in its market.
“With Veros COVID-19 in its diagnostic portfolio, Cruinn can now offer customers a rapid, self-contained single-use molecular test that offers laboratory-quality results and can enable improved access and faster diagnosis than a lab-based test, helping to provide exceptional care for patients.
“This will be the first instrument-free molecular test for COVID-19 to enter the Irish market, highlighting the strategic importance of this agreement to Cruinn,” said Aidan Wearen, head of Marketing and Sales for Cruinn. “Sense’s approach to molecular testing delivers great opportunity for accessibility, speed, and clinical value to patients at the point of care.”
Sense Biodetection’s Veros product platform is backed by investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management.